Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

Appointment of Anna Lucsok as Chief Operating Officer of Zynex Medical, Inc. and departure of Chief Operating Officer, Giuseppe Papandrea.

Effective January 27, 2021, Giuseppe Papandrea resigned as Chief Operating Officer of Zynex Medical, Inc. ("Company"), which was not as a result of any disagreements with the Company or its management.

Effective January 27, 2021, the Board of Directors promoted Anna Lucsok, Vice President of Reimbursement to Chief Operating Officer and entered into an employment agreement with Ms. Lucsok.

Since October 2019, Ms. Lucsok served as Vice President of Reimbursement and Sales Operations with Zynex Medical. From February 2018 to October 2019, Ms. Lucsok served as Zynex Medical's Billing Manager. Prior to joining Zynex Medical, from October 2017 to February 2018, she worked in billing and business support for University of Colorado Hospital, and from November 2014 to October 2017, she served the U.S. Air Force mission support in Germany and Japan. In her position as the Vice President of Reimbursement and Sales Operations she was responsible for leading and expanding Zynex's order, reimbursement, patient experience, and inside sales support operations. During her tenure each of these teams have consistently achieved quarterly targets, while also expanding in size. Ms. Lucsok brings more than 9 years of healthcare operations experience as well as critical knowledge of revenue cycle management and medical care collections. Ms. Lucsok holds certification in medical billing as well as completed her degree in Healthcare Administration and Management from Colorado State University.

There is no arrangement or understanding between Ms. Lucsok and any other person pursuant to which she was selected as an officer of the Company. There is no family relationship between Ms. Lucsok and any director or executive officer of the Company, and Ms. Lucsok is not a party to a related party transaction within the meaning of Item 404(a) of Regulation S-K.

Ms. Lucsok has a Degree in Healthcare Administration and Management from Colorado State University.





Pursuant to the employment agreement, the Company and Ms. Lucsok agreed to the
following:



       •      Ms. Lucsok will receive annual base salary of $200,000 and be
              eligible for annual incentive compensation of up to $200,000 in cash
              and up to $100,000 of restricted shares, based upon achievement of
              annual incentive compensation targets established by the Company's
              Board of Directors.




       •      The Company awarded Ms. Lucsok an initial grant of 50,000 restricted
              shares, vesting annually over a four-year period.




       •      Ms. Lucsok will also be eligible to receive quarterly grants equal
              to 5,000 shares of restricted stock, vesting annually over a
              four-year period.




  • Ms. Lucsok will be employed "at will."




       •      If the Company terminates Ms. Lucsok's employment for reasons other
              than cause or disability, or Ms. Lucsok resigns for "Good Reason,"
              as such terms are defined in her employment agreement, the Company
              will pay Ms. Lucsok severance equal to six months of her base
              salary. The Company will also pay a proportionate amount of
              Ms. Lucsok's health and dental insurance premiums, based upon the
              same proportion the Company paid at the time Ms. Lucsok's employment
              was terminated, for the applicable severance period or until
              Ms. Lucsok obtains substitute insurance. Severance and insurance
              premium payments will be made in equal installments over the
              applicable 6-month period, based upon the Company's normal payroll
              practices.




       •      Ms. Lucsok agreed that following termination of employment she will
              not compete with the Company (as defined in the employment
              agreement), or solicit or entice any employee of the Company to
              leave the employ of the Company or interfere with the Company's
              relationship with a customer during the period of time that
              severance is paid.

The full text of the employment agreement is attached as Exhibit 10.1 to the Current Report on Form 8 K and is qualified in its entirety thereby.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS






d)      Exhibits. The following exhibits are filed with this report.



Exhibit No.                             Description

10.1 Employment Agreement effective January 27, 2021, entered into


            between Zynex Medical, Inc. and Anna Lucsok

99.1 Press Release

© Edgar Online, source Glimpses